USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended July 3, 1999, and the six months ended on that date. USANA Health Sciences Inc. develops and manufactures nutritional, personal care, and weight management products distributed via a network marketing system. As of July 3, 1999, the company operated in the United States, Canada, Australia, New Zealand, and the United Kingdom, with approximately 118,000 current distributors and 37,000 Preferred Customers.
Key Financial Metrics
| Metric | Quarter Ended July 3, 1999 | Six Months Ended July 3, 1999 |
|---|---|---|
| Net Sales | $32.5 million | $63.8 million |
| Gross Profit | $26.1 million (80.5% margin) | $51.1 million (80.1% margin) |
| Net Earnings | $2.2 million | $4.4 million |
| Diluted EPS | $0.17 | $0.33 |
| Operating Cash Flow | Filing text does not provide a clear value for the quarter | $5.2 million |
| Cash and Equivalents | $2.2 million | $2.2 million (Ending Balance) |
| Working Capital | $9.0 million | $9.0 million (Ending Balance) |
| Debt | No outstanding balance on line of credit | No outstanding balance on line of credit |
Liquidity: The company maintains a $10.0 million line of credit expiring May 31, 2000, with no outstanding balance as of July 3, 1999. The company is in compliance with all restrictive covenants.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.1% for the quarter and 11.8% for the six months compared to the prior year periods. Growth was driven by a 31.4% increase in the total customer base.
- Profitability: Net earnings decreased 6.7% for the quarter ($2.2M vs $2.4M) but increased 0.7% for the six months ($4.4M vs $4.3M). Profit margins declined slightly due to increased operating expenses.
- Expense Trends: Selling, general, and administrative (SG&A) expenses rose significantly (22.5% for the quarter, 27.5% for six months) due to international expansion costs, infrastructure building, and depreciation. Distributor incentives as a percentage of sales decreased slightly (44.5% for the quarter) due to compensation plan adjustments.
- Market Expansion: Sales in Australia-New Zealand grew 56.2% for the quarter and 121.7% for the six months. The United Kingdom market, launched in late 1998, contributed $0.7 million in quarterly sales.
Outlook, Risks, and Unusual Items
- Guidance & Outlook: Management expects SG&A expenses to remain under pressure as a percentage of sales throughout 1999 due to planned expansions into the Netherlands and Hong Kong in the third and fourth quarters. The company anticipates international operations will account for an increasing percentage of net sales.
- Related Party Transaction: The company entered into a Promissory Note and Redemption Agreement with its President and CEO, Dr. Myron W. Wentz, allowing for advances up to $5.0 million. Repayment is made via the redemption of Dr. Wentz's shares. As of August 6, 1999, the full $5.0 million had been advanced. This transaction reduces the number of shares outstanding, which is anti-dilutive to other shareholders.
- Legal Proceedings: The company is involved in litigation in the U.S. Federal District Court for the District of Connecticut regarding its rights to sell the Proflavanol product.
- Year 2000 Risk: The company is assessing Year 2000 compliance for its systems and third-party vendors. It is installing a new Enterprise Resource Planning (ERP) system expected to be complete in Q1 2000, which is certified as Year 2000 compliant.
Investor Verification Checklist
- Share Redemption Impact: Verify the exact number of shares retired under the Dr. Wentz agreement and the resulting impact on diluted EPS calculations for future periods.
- International Margins: Monitor the profitability of new markets (UK, Netherlands, Hong Kong) as the company notes higher relative costs and potential inefficiencies in these regions.
- Proflavanol Litigation: Track the status of the Connecticut litigation, as the Proflavanol product represented approximately 16% of net sales for the six months ended July 3, 1999.
- SG&A Leverage: Assess whether the company can achieve operating leverage as sales grow, given the current trend of SG&A increasing faster than revenue.
- Year 2000 Readiness: Confirm the successful installation and testing of the new ERP system to mitigate operational risks associated with the millennium rollover.